Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Apalutamide + SX-682 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Apalutamide | Erleada | ARN-509|JNJ-56021927 | Hormone - Anti-androgens 57 | Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
| SX-682 | SX682|SX 682 | CXCR Antagonist 4 | SX-682 is an inhibitor of the C-X-C chemokine receptor types, CXCR1 and CXCR2, resulting in reduced neutrophil chemotaxis and decreased tumor cell tumor cell migration (PMID: 31848188). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07002320 | Phase Ib/II | Apalutamide + SX-682 | Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (ASpiRE) | Recruiting | GBR | CHE | 0 |